Search the Newsreel

FutureCrest Acquisition Ord Shs Class A (FCRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article from TradingKey reports on FutureCrest Acquisition Ord Shs Class A (FCRS) and its revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides basic stock information …

Earnings call transcript: Silvercrest Asset Management posts mixed Q2 2026 results

Silvercrest Asset Management (SAMG) reported mixed Q2 2026 results, with adjusted EPS missing analyst expectations at $0.10, but revenue slightly exceeding forecasts at $30.78 million. The company saw discretionary assets under management reach an all-time high of $24.7 billion and reported increased organic new …

Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003

Crescent Biopharma announced its Q2 2026 financial results and provided updates on its clinical pipeline, including CR-001, CR-002, and CR-003. The company is progressing enrollment in the ASCEND Phase 1/2 trial for CR-001 and anticipates key clinical data readouts starting in Q1 2027. Crescent …

Cresud SACIF y A (CRESY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Cresud SACIF y A (CRESY), noting its current valuation score of 9.29, which ranks 17th in the Food & Tobacco industry. The P/E ratio stands at 4.58, indicating a significant drop from its recent high and a …

Silvercrest (SAMG) Stock Faces Margin Strain Behind Record AUM

Silvercrest Asset Management Group (SAMG) reported Q2 2026 earnings with record Assets Under Management (AUM) but faced significant margin strain, leading to a 90-91% decline in net income and EPS year-over-year. Despite a 3.8% stock increase, the company's profitability remains thin with an 11.2% …

Crescent Biopharma: Q2 Earnings Snapshot

Crescent Biopharma (CBIO) reported a Q2 loss of $24.8 million, or 74 cents per share, missing Wall Street expectations of a 70-cent loss. This financial update was generated by Automated Insights using data from Zacks Investment Research.

Crescent Biopharma (NASDAQ: CBIO) registers 18.2M shares for investor resale

Crescent Biopharma (NASDAQ: CBIO) has filed a post-effective amendment to convert an existing Form S-1 into a Form S-3 shelf registration, allowing for the resale of up to 18,154,836 Ordinary Shares by existing investors. These shares include those from a December 2025 private placement, …

Silvercrest Asset Management Group Inc. to Issue Quarterly Dividend of $0.21 (NASDAQ:SAMG)

Silvercrest Asset Management Group (NASDAQ:SAMG) Issues Quarterly Earnings Results

Analysts Offer Insights on Real Estate Companies: Rithm Capital (RITM) and ACRES Commercial Realty (ACR)

Crescent Biopharma Files Prospectus Supplement Reflecting Q2 2026 Financials and Share Resale Update

Crescent Biopharma, Inc. has filed a prospectus supplement on July 30, 2026, updating its securities registration to include the company's Q2 2026 financial results, which ended on June 30, 2026. The update also reflects the resale of approximately 19.6 million ordinary shares by existing …

Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update

Crescent Biopharma, Inc. released its financial results for the second quarter ended June 30, 2026, on July 30, 2026. The biopharmaceutical company submitted a formal disclosure to the Securities and Exchange Commission detailing its operational and financial metrics. This announcement highlights the company's ongoing …

Silvercrest Asset Management Group Inc. Reports Q2 2026 Results

Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) reported its second-quarter 2026 results, showing an increase in discretionary assets under management to $24.7 billion despite client outflows. The company is actively expanding its global infrastructure and distribution, expecting to complete its MiFID license by Q3 …

CRESY|Cresud SACIF y A|Price:11.620|Chg%:+0.260

This article provides a detailed financial overview of Cresud SACIF y A (CRESY), including its latest earnings, revenue, EPS, and analyst ratings, which currently stand at "STRONG BUY." It presents comprehensive quarterly and annual financial statements such as income statements, balance sheets, and cash …

ACRES Commercial Realty: Why We Are Staying Neutral On ACRES Series C Preferred (ACR.PR.C)

ACRES Commercial Realty Corp. (ACR) reported a disappointing Q2 2026 with a 10% drop in book value per share and significant one-time costs from management internalization. The company's capital structure is heavily weighted towards preferred equity, which raises concerns for preferred shareholders. As a …

Crescent Energy (CRGY) Gains But Lags Market: What You Should Know

In the latest close session, Crescent Energy (CRGY) was up +1.09% at $11.17. This change lagged the S&P 500's 1.66% gain on the day. Meanwhile, the Dow gained 1.19%, and the Nasdaq, a tech-heavy index, added 2.78%. Shares of the oil and gas company …

Is Silvercrest Asset Management Group Inc (SAMG) Positioned for

ACRES Commercial Realty Reports Quarterly Net Loss, Internalizes Management

ACRES Commercial Realty (ACR) reported a GAAP net loss of $12.5 million, or $1.87 per diluted share, for the quarter ending June 30, 2026. Despite the loss, management is focusing on a healthy pipeline of new loan opportunities, selective asset additions, and an internalization …

Form 4 CRESUD INC For: 30 July By Investing.com

The article reports on a Form 4 filing for CRESUD INC related to July 30, with the stock symbol CRESY showing a -3.45% change. It appears to be a brief financial news update from Investing.com. The content primarily focuses on this specific regulatory filing …

Silvercrest declares a $0.21 quarterly dividend after Q2 results

Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) reported Q2 2026 revenue of $30.8 million and GAAP net income of $0.5 million, with adjusted EBITDA of $3.4 million. The company's total AUM reached $37.0 billion, including $24.7 billion in discretionary AUM, and its board declared …

Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) Director Sells $88,200.00 in Stock

Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) Director Fernando Adrian Elsztain sold 70,000 shares of the company's stock for $88,200.00, reducing his position by 9.27%. The transaction took place on Thursday, June 11th, at an average price of $1.26 per share. The company's stock traded up …

ACRES Commercial Realty Corp (ACR) (Q2 2026) Earnings Call Highlights: Internalization ...

ACRES Commercial Realty Corp (ACR) reported a GAAP net loss of $12.5 million ($1.87 per share) for Q2 2026, primarily due to internalization transaction costs and compensation expenses, though net interest income increased. Shareholders approved the internalization of the external manager, which management believes …

Crescent Biopharma reports Q2 2026 net loss $24.8M, cash $171.6M and $143.7M public offering

Crescent Biopharma reported a net loss of $24.8 million for Q2 2026, an increase from $21.8 million in Q2 2025. The company held $171.6 million in cash and cash equivalents as of June 30, 2026, which increased to a pro forma $305.1 million after …

Crescent Biopharma reports Q2 2026 results, advances cancer drug trials, and raises $143.7M to fund operations through 2028

Crescent Biopharma announced its second quarter 2026 financial results, highlighting significant progress in clinical trials for its cancer therapies, including CR-001, CR-002, and CR-003, with key data anticipated from Q1 2027. The company successfully completed a $143.7 million public offering, extending its cash runway …

Crescent Biopharma posts $24.8 million Q2 net loss

Crescent Biopharma (CBIO) reported a net loss of $24.8 million, or $0.74 per basic and diluted share, for the second quarter of 2026. The company is advancing its clinical pipeline, including continued enrollment in the ASCEND Phase 1/2 trial for CR-001 and other trials …

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma reported its second-quarter 2026 financial results, highlighting significant progress in its clinical trials for CR-001, CR-002, and CR-003, with multiple data readouts anticipated in 2027. The company recently completed a $143.7 million public offering, extending its cash runway into the second half …

Cresud director Fernando Adrian Elsztain sells USD 124,100 in common shares

Cresud director Fernando Adrian Elsztain sold 101,000 common shares in two transactions in April and June 2026, totaling USD 124,100. Following these sales, his direct holding in the company decreased to 685,121 common shares. This news brief was generated by AI based on information …

Fernando Adrian Elsztain Sells 15,000 Shares of Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) Stock

Fernando Adrian Elsztain, a Director at Cresud S.A.C.I.F. y A. (NASDAQ:CRESY), sold 15,000 shares of the company's stock on July 21st at an average price of $1.13, totaling $16,950. This transaction reduced his holdings by 2.20% to 665,736 shares. The article also notes several …

Silvercrest Asset Mgmt Q2 EPS $0.10, Sales $30.8M Beat

ADAR1 Capital Management LLC Sells 555,727 Shares of Crescent Biopharma, Inc. $CBIO

Silvercrest Asset Management Group (NASDAQ:SAMG) Stock Rating Upgraded by Zacks Research

SAMG|Silvercrest Asset Management Group Inc|Price:10.210|Chg%:+0.070

ACRES Commercial Realty Corp. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ACR) 2026-07-30

ACRES Commercial Realty Corp (ACR) reported a GAAP net loss of $12.5 million ($1.87 per share) for Q2 2026, primarily due to internalization transaction costs and compensation expenses, though net interest income increased. Shareholders approved the internalization of the external manager, which management believes …

Crescent Biopharma (NASDAQ:CBIO) Issues Earnings Results, Misses Estimates By $0.04 EPS

Crescent Biopharma (Nasdaq: CBIO) posts Q2 loss, extends cash runway to 2028

Silvercrest (SAMG) Q2 Earnings and Revenues Miss Estimates